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Abstract
Human body weight is maintained at a fairly stable level regardless of changes in energy intake and energy expenditure. Compensatory
mechanisms within the central nervous system (CNS), which regulate food intake and energy expenditure, are triggered by other central
and peripheral signals. Peripherally, the main sources of those signals are the adipose tissue, gastrointestinal tract, and pancreas. The main
signal originating from the adipose tissue is leptin, which promotes the activation of anorexigenic pathways in the CNS. Similarly, the
central action of insulin also reduces food intake and stimulates catabolic pathways. The gastrointestinal tract contributes with several
peptides that influence food intake, such as ghrelin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin (OXM), and
cholecystokinin (CCK). Other substances secreted by the pancreas, such as pancreatic polypeptide (PP) and amylin, a hormone co-secret-
ed with insulin, also affect energy balance. More recently, the endocannabinoid system has also been identified as a contributor in the
maintenance of energy balance. Better understanding of these mechanistic systems involved in the regulation of energy metabolism will
hopefully lead to the development of new therapeutic approaches against obesity, metabolic syndrome, and other nutritional disorders.
(Pol J Endocrinol 2010; 61 (2): 194–206)
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Streszczenie
Masa ciała człowieka jest utrzymywana  na względnie stałym poziomie niezależnie od zmian zarówno w dostarczaniu energii, jak i jej
zużywania. Mechanizm kompensacyjny w ośrodkowym układzie nerwowym (CNS, central nervous system [OUN]), który reguluje przyj-
mowanie pokarmu i wydatek energii jest uruchamiany przez inne sygnały ośrodkowe i obwodowe. Obwodowo, źródłem tych sygnałów
jest  tkanka tłuszczowa, układ pokarmowy i trzustka. Głównym sygnałem pochodzącym z tkanki tuszczowej jest leptyna, która powoduje
aktywację anoreksogennych dróg przekazu sygnału w CNS. Podobnie, oddziaływanie ośrodkowe insuliny także zmniejsza przyjmowa-
nie pokarmu i stymuluje kataboliczne drogi przekazu sygnału.
W układzie pokarmowym współdziała kilka peptydów, które wpływają na przyjmowanie pokarmu, takie jak grelina, peptyd podobny do
glukagonu (GLP-1, glucagon-like peptide), peptyd YY (PYY, peptide YY), oksyntomodulina  (OXM, oxyntomodulin) i cholecystokinina (CCK,
cholecystokinin), Pozostałe substancje wydzielane przez trzustkę, takie jak polipeptyd trzustkowy (PP, pancreatic polypeptide)
i amylina, hormon wydzielany jednocześnie z insuliną , także wpływają na równowagę energetyczną. W najnowszych badaniach stwier-
dzono, że układ endokannabinoidowy przyczynia sie do zachowania równowagi energetycznej. Lepsze zrozumienie mechanizmów
układów wpływających na regulacje przemiany energii przyczyni się do rozwoju nowych terapii otyłości, zespołu metabolicznego
i innych zaburzeń odżywiania. (Endokrynol Pol 2010; 61 (2): 194–206)
Słowa kluczowe: ośrodkowy układ nerwowy, otyłość, trzustka
Introduction
The human body is endowed with a complex physio-
logical system that maintains relatively constant body
weight and fat stores despite the wide variations in daily
energy intake and energy expenditure. With weight
loss, compensatory physiological adaptations result in
increased hunger and decreased energy expenditure,
while opposite responses are triggered when body
weight increases. This regulatory system is formed by
multiple interactions between the gastrointestinal tract
(GIT), adipose tissue, and the central nervous system
(CNS) and is influenced by behavioural, sensorial, au-
tonomic, nutritional, and endocrine mechanisms. From
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an evolutionary point of view, it has been suggested
that these control mechanisms are developed primari-
ly to increase survival in times of food shortages. Con-
sequently, they are more active and promote a more
robust physiological response during weight loss than
weight gain, which is undesirable in the face of the cur-
rent pandemic of obesity [1–3].
The hypothalamus — particularly the arcuate nu-
cleus (ARC) — and the brain — particularly the nucle-
us of the solitary tract (NTS) — are the main sites of
convergence and integration of the central and periph-
eral signals that regulate food intake and energy expen-
diture [4, 5]. There are mechanisms of short-term regu-
lation („satiety signals”) which determine the beginning
and end of a meal (hunger and satiation) and the inter-
val between meals (satiety) [6], and long-term regula-
tory factors („signals of adiposity”) which help the body
to regulate energy depots. Satiety signals from the GIT
are transmitted primarily through vagal and spinal nerves
to the NTS, while the signals of adiposity reach the me-
dian eminence via ARC or by crossing the blood-brain
barrier (BBB) through saturable and non-saturable mech-
anisms. There is, however, a large integration and con-
vergence of these signals by neural connections between
the ARC nucleus, NTS, and vagal afferent fibres.
In recent years, the central regulation of energy bal-
ance has become even more fascinating and complex
with the characterization of new mechanisms of con-
trol. The endocannabinoid system participates in ener-
gy homeostasis by central and peripheral actions that
influence appetite, motivation for consumption of pal-
atable food, production and distribution of fat, energy
expenditure, and glucose and insulin homeostasis [7].
These new findings on the neuroendocrine mechanisms
controlling energy homeostasis and body weight show
the complexity of these integrating systems and the
existence of many unravelled mysteries (Fig. 1). Never-
theless, each mystery unveiled opens new opportuni-
ties for the development of novel therapies for obesity
and nutritional disorders [8].
Leptin, insulin, and neuroendocrine
control of energy balance
Leptin
Leptin is a peptide hormone produced by the ob gene
and secreted mainly by the adipose tissue, playing
a key role in energy homeostasis. The production of lep-
tin is higher in subcutaneous fat than in visceral fat, and
in the blood, leptin levels correlate directly with the
amount of body fat. The secretion of leptin is reduced
during periods of fasting and increased after meals, and
is influenced by several metabolic and hormonal factors
[9]. Congenital leptin deficiency due to genetic defects
in the ob gene results in early-onset obesity associated
with hyperphagia, decreased energy expenditure, and
endocrine abnormalities. Similarly, patients with congen-
ital or acquired lipodystrophy also have low leptin levels
associated with insulin resistance and dyslipidemia [10].
Administration of recombinant leptin can reverse this
phenotype both in animals and humans [10–12]. Low
leptin levels are also observed in patients with anorexia
nervosa and hypothalamic amenorrhea [13].
Leptin is transported to the brain where it crosses
the BBB in a saturable mechanism and binds to its spe-
cific receptor (Ob-R, encoded by the db gene) in the ARC
nucleus of the hypothalamus. Ob-R belongs to the type
I cytokine receptor family and exists as five distinct iso-
forms (splice variants) named Ob-Ra, Ob-Rb, Ob-Rc,
Ob-Rd, and Ob-Re. Only the Ob-Rb isoform contains
a long intracellular domain essential for biological actions
of leptin, while the physiological roles of the short iso-
forms are related to the transport of leptin in the circu-
lation and through the BBB [14–16]. The Ob-Rb is high-
ly expressed in hypothalamic nuclei — particularly ARC
nucleus, ventro-medial, dorso-medial, and lateral hy-
pothalamus. Leptin receptors are also present in sever-
al areas of the brainstem including the nucleus tractus
solitarii (NTS), lateral parabrachial nucleus, and motor
and sensory nuclei, which are not normally associated
with energy balance. The presence of Ob-Rb in brain
areas such as the NTS indicates that leptin effects are
due, at least in part, to actions in the brainstem [17].
Peripherally, Ob-Rb is expressed in the lungs, kidneys,
liver, pancreas, adrenals, ovaries, stem cells, and he-
matopoietic skeletal muscle. These peripheral locations
of Ob-R evidence the multiplicity of different biologi-
cal functions exerted by leptin in the body, in addition
to its role in energy homeostasis. Mutations in the db
gene have also been associated with monogenic obesi-
ty in both rodents and humans [11, 16], characterized
by normal or elevated levels of leptin and the lack of
a response to the administration of recombinant leptin.
Leptin stimulates anorexigenic neurons that express
pro-opiomelanocortin (POMC) and cocaine- and am-
phetamine-regulated transcript (CART), and it inhibits
orexigenic neurons that express neuropeptide Y (NPY)
and Agouti-related peptide (AgRP). These primary tar-
gets of leptin action communicate with the second-or-
der neurons in other hypothalamic nuclei (especially
paraventricular nucleus, dorso-medial, ventro-medial
and lateral hypothalamus), where peripheral informa-
tion on energy depots is integrated with behavioural,
hormonal, and nutritional inputs coming from the pe-
riphery and higher cortical centres. Several hypotha-
lamic neurotransmitters produced in these regions, in-
cluding corticotropin releasing hormone (CRH), thy-
rotropin releasing hormone (TRH), melanin concentrat-
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ing hormone (MCH), brain-derived neurotrophic fac-
tor (BDNF), oxytocin, and orexins, are physiologically
involved in energy homeostasis. Leptin indirectly in-
hibits or stimulates these peptides, contributing to the
regulation of energy intake and thermogenesis (Fig. 1,
left panel). These orexigenic and anorexigenic neuronal
Figure 1. Central actions of leptin and insulin. Left Panel. Leptin and insulin are transported to the brain, where they cross the blood–
brain barrier (BBB) and bind to their specific receptors in two neuronal populations of the arcuate nucleus (ARC) of the hypothalamus:
POMC/CART neurons, where they stimulate a-MSH expression, and NPY/AgRP orexigenic neurons, where they inhibit NPY/AgRP
expression. These primary targets of leptin and insulin action communicate with the second-order neurons in other hypothalamic nuclei,
especially the paraventricular nucleus (PVN) and lateral hypothalamus (LH), stimulating expression of anorexigenic neurotransmitters
(CRH, TRH) and inhibiting orexigenic pathways (orexin, MCH). The final biological actions of central leptin and insulin action are
inhibition of food intake and stimulation of thermogenesis. Right Panel. Leptin binding to Ob-Rb promotes activation of JAK and
STAT3 proteins, while insulin binding to IR stimulates IR substrates (IRSs), especially IRS-2. Simultaneously, the activation of JAK,
STAT, and IRSs proteins leads to the expression of inhibitors of leptin and insulin signalling such as SOCS-3 and PTP1B.
POMC — pro-opiomelanocortin; CART — cocaine- and amphetamine-regulated transcript; a-MSH — melanocyte-stimulating hormone
(melanocortin); NPY — neuropeptide Y; AgRP — agouti-related peptide; CRH — corticotropin-releasing hormone; TRH — thyrotropin-
releasing hormone; MCH — melanin-concentrating hormone; Ob-Rb — leptin receptor; JAK — janus kinase; STAT — signal transducer
and activator of transcription; SOCS-3 — suppressor of cytokine signaling-3; PTP1B — protein tyrosine phosphatase-1B
Rycina 1. Działanie ośrodkowe leptyny i insuliny. Strona lewa — leptyna i insulina są transportowane do mózgu, gdzie przekraczają
barierę krew–mózg (BBB) i łączą się ze swoistymi receptorami w dwóch populacjach neuronów: w jądrze łukowatym (ARC) podwzgórza:
neuronami POMC/CART, gdzie stymulują ekspresję a-MSH i neuronami oreksygenicznymi NPY/AgRP, w których hamują ekspresję
NPY/AgRP. Te pierwotne cele działania leptyny i insuliny komunikują się z neuronami drugiego rzędu w innych jadrach podwzgórza,
szczególnie w jądrze przykomorowym (PVN) i podwzgórzem bocznym (LH) stymulują ekspresję neurotransmiterów anoreksogennych
(CRH, TRH) i hamując oreksygeniczne szlaki przekazywania sygnału (orexin, MCH). Końcową aktywnością biologiczną centralnego
działania leptyny i insuliny jest zahamowanie przyjmowania pożywienia i stymulacja termogenezy. Strona prawa — leptyna łącząc
się z Ob-Rb, promuje aktywację białek  JAK i STAT3, podczas gdy insulina łącząc się z IR, stymuluje substraty IR, czyli IRSs, szczególnie
IRS-2. Jednoczesnie aktywacja białek JAK, STAT i IRSs prowadzi do ekspresji inhubitorów przekazywania sygnałów leptyny i insuliny,
takich jak SOCS i PTP1B.
POMC — proopiomelanokortyna; CART — transkrypt regulowany przez kokainę i amfetaminę; a-MSH — hormon stymulujacy
melanocyty, melanokortyna; NPY — neuropeptyd Y; AgRP — białko agouti; CRH — hormon uwalniający kortykotropinę; TRH —
hormon uwalniający tyreotropinę; MCH — hormon zwiększający stężenie melaniny; Ob-Rb – receptor leptyny; JAK — kinaza janusa;
STAT — przekaźnik sygnału i aktywatory transkrypcji; SOCS-3 — supresor przekazu sygnału cytokin — 3; PTP1B — białkowa
fosfataza tyrozyny 1B
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groups are connected at several points in the CNS in
such a manner that the activation of one group inhibits
the other and vice-versa [1–4].
The binding of leptin to Ob-Rb promotes receptor
dimerization, activation of JAK and STAT proteins, and
subsequent phosphorylation of cytoplasmic proteins,
leading to the signal transmission to the nucleus and
modulation of gene transcription. Simultaneously, the
activation of JAK and STAT proteins leads to the ex-
pression of inhibitors of signalling such as SOCS-3 (sup-
pressor of cytokine signalling 3) and PTP1B (protein
tyrosine phosphatase-1B), which modulate the biologi-
cal response to leptin [18, 19] (Fig. 1, right panel). Lep-
tin is the main catabolic adiposity signal, the actions of
which result in reduced food intake, increased energy
expenditure, and weight loss.
Serum leptin levels are low in anorexia nervosa and
show a progressive increase with the reinitiation of food
intake and recovery of body weight. Conversely, hu-
man obesity is generally associated with high serum
levels of leptin and less efficient transport across the
BBB, consistent with a state of central resistance to lep-
tin. This resistance may be secondary to obesity or vice-
versa, and genetic factors, age, diet, sedentary lifestyle,
and stress might contribute to the development of de-
fects in the transport of leptin across the BBB or might
lead to abnormalities in leptin signalling [2, 9]. The latter
might potentially involve increased intracellular expres-
sion of SOCS-3, as genetically modified animals that do
not express neuronal SOCS-3 are resistant to diet-induced
obesity. Moreover, it has been shown that obese subjects
show increased neuronal SOCS-3 activity [2, 8]. Other
factors that alter leptin signalling, leading to a decrease
in its effects, are serum leptin-interacting proteins (such
as C-reactive protein), PTP1B, and P-STAT [19, 20].
When obese subjects are subjected to diet-induced
weight loss, there is deterioration in the central trans-
port of leptin and subsequent worsening of leptin re-
sistance. This is one of the mechanisms that explain the
well-known problem in maintaining negative energy
balance during weight loss. In a clinical trial, we showed
that a catecholaminergic drug, licensed in some coun-
tries as an anti-obesity agent, increased the cerebro-spi-
nal fluid (CSF)/serum leptin ratio after weight loss, sug-
gesting an improvement of leptin transportation to the
CNS [21]. This catecholaminergic effect was greater than
that seen with sibutramine (a drug with serotoninergic
and catecholaminergic combined effects), and it was not
observed after weight loss induced by orlistat (a drug
with no central effect), indicating that the anorexigenic
effect of catecholamine is partly due to an increased
hypothalamic sensitivity to leptin [21]. In agreement
with our clinical findings, Banks demonstrated in rats
that leptin transport across the BBB is enhanced only
by adrenergic agents [22]. On the other hand, serotonin-
ergic drugs, such as fenfluramine, dexfenfluramine, and
sibutramine can promote anorexia by binding to the
serotonergic 5-HT2C receptors expressed in POMC
neurons, activating the same anorexigenic pathways
that are critical for the biological effects of leptin. There
is evidence that the concomitant activation of seroton-
ergic 5-HT1B receptors, which are expressed in NPY/
/AgRP neurons, could produce an even greater cata-
bolic effect and be a target for the development of new
anorexigenic drugs [8]. Apart from resistance to leptin,
lower production of leptin by the adipose tissue, which
has been observed in individuals heterozygous for in-
activating mutations in the ob gene, is associated with
an increased prevalence of overweight and obesity in
this population, suggesting that partial or relative lep-
tin deficiency may be also an aetiological mechanism in
human obesity [23]. Accordingly, we have found that
leptin production by the adipose tissue is decreased in
obese subjects with three or more risk factors for meta-
bolic syndrome, suggesting a state of relative leptin
deficiency in obesity associated with advanced stages
of metabolic syndrome [24].
Despite its action on decreasing food intake, leptin
replacement has not been shown to be an effective treat-
ment for common obesity. Clinical trials in an obese
population led to very modest, if any, weight loss after
leptin replacement [25–27]. However, patients with rel-
atively low leptin levels showed better therapeutic re-
sponses, and future studies need to show whether lep-
tin replacement can be useful in treating selected obese
patients. In addition, co-administration of recombinant
human leptin with pramlintide — an amylin agonist —
may yield significantly greater weight loss than either
agent alone [28].
Insulin
The central action of insulin promotes the same biolog-
ical effects as leptin, characterizing insulin as an adi-
posity signal [29] (Fig. 1, left panel). Serum levels of in-
sulin are proportional to the amount of body fat and
are influenced by peripheral insulin sensitivity, which
is chiefly determined by the amount of visceral fat. In-
sulin crosses the BBB and binds to the insulin receptor
(IR) present in high concentrations in neurons POMC/
/CART and NPY/AgRP in the ARC nucleus. Several stud-
ies have shown that the central action of insulin pro-
motes anorexia, increases energy expenditure, and re-
duces body weight. In animals, reduced expression or
deletion of the neuronal IR results in hyperphagia, obe-
sity, and dyslipidemia, with high peripheral levels of
insulin [30, 31]. In humans, the central anorexigenic ef-
fects of insulin are potentially important for the future
development of insulin analogues with higher and fast-
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er hypothalamic signalling compared to their periph-
eral actions, in order to avoid the weight gain commonly
observed in the treatment of diabetes [32].
The IR is composed of an extracellular a sub-unit
that binds to insulin and an intracellular b sub-unit that
carries the signal and has intrinsic tyrosine kinase activi-
ty. Among various IR substrates (IRS), IRS-1 and IRS-2
are identified in neuronal cells with high expression of
messenger RNA (mRNA) of IRS-2 in the ARC nucleus.
Neuronal IRS-2 knock-out animals show increased food
intake, and increased adiposity and infertility, suggest-
ing that the central effects of insulin are mediated by
this substrate [33]. Ob-Rb and IR share intracellular sig-
nalling pathways by PTP1B, JAK 2, and IRS [2, 29, 34]
(Fig. 1, right panel). PTP1B inhibition seems to increase
insulin and leptin sensitivity as PTP1B knock-out ani-
mals are lean, insulin sensitive, and resistant to diet-
induced obesity [35].
In addition to regulating energy intake, both insu-
lin and leptin have direct effects on adipose tissue: lep-
tin stimulates lipolysis and insulin increases lipogene-
sis. Within the so-called adipoinsular axis, leptin exerts
an inhibitory feedback on pancreatic insulin secretion
in order to decrease lipogenesis. Insulin, in turn, also
plays a role in stimulating leptin production and secre-
tion in the adipose tissue [36].
Integration of peripheral signals in the CNS:
neuropeptide Y (NPY) and the melanocortin
system
NPY is the most abundant neurotransmitter in the brain
and is expressed in the hypothalamus mainly by neu-
rons of the ARC nucleus. As expected for an orexigenic
factor, hypothalamic NPY levels increase during fast-
ing and decrease after feeding [3]. NPY integrates a large
family of peptides that includes peptide YY (PYY) and
pancreatic polypeptide (PP), the effects of which are
mediated via six G-protein-coupled receptors named
Y1 to Y6. It is likely that the orexigenic effects of NPY
are mediated by a combination of these receptors and
not by only one [37].
The obese phenotype of ob/ob mice is attenuated by
the loss of NPY [29]. In contrast, mice genetically defi-
cient in NPY have normal food intake and body weight,
suggesting the presence of alternative orexigenic mech-
anisms to compensate for the absence of NPY [38]. The
redundancy of orexigenic pathways may be linked to
evolutionary mechanisms for protection against star-
vation. Today, in the presence of epidemic obesity, these
redundant pathways might partly explain the easy re-
covery of weight observed in obese individuals under-
going treatment, since weight reduction leads to a de-
crease in leptin, activation of NPY, and, consequently,
hyperphagia and reduced metabolic expenditure. The
melanocortin system refers to a group of peptides that
originate from the cleavage of POMC — including
adrenocorticotropic hormone (ACTH) and melanocyte-
-stimulating hormones (MSHs) — five different sub-
types of G-protein-coupled receptors, and the endoge-
nous antagonists AgRP and Agouti. This system has
many important physiological roles in pigmentation,
adrenocortical steroidogenesis, natriuresis, erection, and
exocrine secretion. Moreover, various components of the
melanocortin system play a role in energy balance [39].
In the ARC nucleus, the cleavage of POMC results
in the production of a-MSH, which, by binding to its
MC4 receptor (MC4R) situated in other hypothalamic
nuclei, produces anorexia. There is evidence demon-
strating the physiological role of the melanocortin path-
way on the regulation of food intake and body weight
[3, 39]. Fasting animals and ob/ob mice have low expres-
sion of POMC mRNA, which is reversed by leptin ad-
ministration. MC4R agonists suppress food intake,
whereas selective antagonists promote the opposite effect.
The absence of MC4R in genetically modified animals caus-
es hyperphagia and obesity, which is also observed in the
Agouti mouse. In this model, the production of the Agou-
ti protein inhibits the action of a-MSH on the MC1R in
the skin, resulting in discoloration of hair, and on the MC4R
in the hypothalamus, leading to hyperphagia and obesi-
ty. AgRP (Agouti homologous human protein) is another
orexigenic factor synthesized in the same neurons of the
ARC nucleus that express NPY, which acts as an endoge-
nous antagonist to MC3R and MC4R, inhibiting the anor-
exigenic effects of a-MSH [3, 39].
Besides MC4R, a possible role of MC3R in energy
homeostasis has been investigated, but the results are not
conclusive yet [39]. It has been suggested that MC3R acts
as a self-inhibitory receptor in POMC neurons, and its
stimulation causes increased food intake. In contrast, its
absence produces an unusual syndrome in MC3R knock-
out animals, characterized by moderate obesity, mild or
absent hyperphagia, mild insulin resistance, mild steato-
sis, no increment in lean mass, and increased fat in both
sexes, but with weight gain seen only in females [40, 41].
In humans, mutations in the POMC gene and ab-
normalities in its processing result in obesity associated
with early-onset adrenal insufficiency and red hair [42].
In some populations, functional abnormalities of the
MC4R have been implicated as a monogenic cause of
obesity in up to 6% of individuals, with recent indica-
tions that its true prevalence varies from 1 to 2.5% in
subjects with body mass index (BMI) > 30 kg/m2. These
percentages confirm MC4R mutations as one of the most
prevalent genetic defects in human obesity, at least in
some populations [11].
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Other adipocytokines involved in energy balance
The adipose tissue produces numerous other factors
that may directly or indirectly influence the energy bal-
ance and body weight [43, 44] (Table I). Adiponectin is
one of these factors. Adiponectin-deficient mice devel-
op insulin resistance, glucose intolerance, dyslipidemia,
and susceptibility to vascular injury and atherosclero-
sis. However, the absence of adiponectin does not seem
to alter energy intake or thermogenesis [45, 46]. Cen-
tral injection in rats increases energy expenditure and
decreases fat mass and body weight without affecting
food intake. In turn, peripheral administration of adi-
ponectin results in less weight gain and improvements
in insulin sensitivity and dyslipidemia. Those effects are
possibly mediated by sympathetic activation. In hu-
mans, serum adiponectin levels are inversely related to
adiposity and insulin resistance, increasing after weight
loss induced by diet or bariatric surgery. Thus, the phys-
iological effect of adiponectin is to increase energy ex-
penditure and to protect against insulin resistance and
atherosclerosis [3, 43, 44]. In fact, recent studies have
shown that adiponectin activates signal transduction
pathways similar to leptin and insulin in the hypothal-
amus, reinforcing its role in the central control of ener-
gy homeostasis [47].
In contrast, resistin is a peptide produced by adi-
pocytes that increases insulin resistance via paracrine
actions. Serum levels of resistin are increased in obesi-
ty, and although it has been suggested as a link be-
tween obesity and diabetes, its pathophysiological rel-
evance is still not clarified [43, 44, 48]. Tumor necrosis
factor-a is correlated with the amount of body fat, and
inhibits feeding, increases metabolic rate, and induces
cachexia [49].
Another potential adipocytokine involved with en-
ergy homeostasis is interleukin-6 (IL-6), which exerts
both paracrine and endocrine effects. Intracerebral ad-
ministration of IL-6 results in increased energy expen-
diture, while IL-6 concentrations in CSF are negatively
correlated with the amount of fat mass. Moreover, the
absence of IL-6 in knock-out animal models has been
associated with obesity in adulthood. Taken together,
these data suggest a potential protective role of IL-6
against the development of obesity [50]. However, the
data are not consistent between different research
groups, and the actual involvement of IL-6 in control-
ling energy requires additional studies [44].
Gastrointestinal peptides
in the control of energy balance
Cholecystokinin
Studies from the 1970s were the first to correlate gas-
trointestinal peptides with the regulation of energy bal-
ance. At that time, cholecystokinin (CCK) — a peptide
predominantly produced in the duodenum and je-
junum — was shown to be involved in the control of
appetite by acting on the vagus nerve or directly into
hypothalamic nuclei [5, 6]. Cholecystokinin reduces
food intake, meal size, and meal duration when admin-
istered to both rodents and humans, by binding to CCKA
receptors. However, the interest in CCK as a therapeu-
tic target for obesity progressively decreased with the
demonstration that animals compensate the reduction
in food intake by increasing the number of meals, with
no change in body weight. Similarly, studies in obese sub-
jects with CCK1R agonists have failed to show any effect
in weight loss or cardiovascular risk factors. Nevertheless,
the initial findings with CCK paved the way to investi-
gate a system that recognizes the presence of food in the
GIT, signalling to the brain via neural and endocrine mech-
anisms to regulate appetite and satiety (Table II). Since
then, several gastrointestinal peptides have been dis-
covered and their therapeutic potential in physiologi-
cal or pharmacological concentrations has been tested
in both animal and humans studies [51].
Ghrelin
Ghrelin is a 28-amino acid peptide produced predomi-
nantly by oxyntic cells of the stomach, and in the intes-
tine, pancreas, and other tissues in smaller quantities.
Table I. Effects of the main adipocytokines on energy
homeostasis
Tabela I. Wpływ głównych adipocytokinin na zachowanie
energii
Adipocytokine Source Function
Leptin Mainly Øfood intake
Adipose tissue ≠satiety
≠energy expenditure
Øinsulin
Øinsulin resistance
Ølipogenesis
≠lipolysis
Adiponectin Adipose tissue Øfood intake
≠energy expenditure
Øinsulin resistance
≠lipolysis
Resistin Macrophages ?
Tumor necrosis Adipose tissue Øfood intake
factor a (TNF-a)  and immune cells ≠satiety
≠insulin resistance
Interleukin 6 Adipose Øfood intake
(IL-6) tissue, ≠satiety
immune cells ≠energy expenditure
and muscle ≠insulin resistance
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Discovered in 1999 as the natural ligand of GHS-R (growth
hormone secretagogues receptor) type 1a, ghrelin stimu-
lates GH secretion in the pituitary gland and exerts other
neuroendocrine activities. In the energy balance, ghrelin
plays an important role as the only known peripheral hor-
mone with orexigenic properties. In healthy volunteers,
intravenous and subcutaneous administration of ghrelin
promotes a 30% increase in food intake [52, 53].
Ghrelin has two forms: 1) acylated ghrelin contains
an n-octanoic acid at the serine-3 position, which is es-
sential for activation of GHS-R1 and modulation of neu-
roendocrine and orexigenic effects; and 2) nonacylated
ghrelin, which is unable to activate GHS-R1 and is de-
void of any endocrine effects; however, nonacylated
ghrelin is the most abundant form in the circulation and
exerts some cardiovascular and antiproliferative actions,
probably by binding different GHS-R subtypes or as yet
unidentified receptor families. GHS-R1a is widely dis-
tributed in the body, with high expression levels in the
hypothalamus and pituitary, and low expression in oth-
er brain areas and in peripheral tissues, particularly in
the endocrine pancreas [52, 53]. The gene encoding
ghrelin also encodes another peptide, called obestatin.
The administration of obestatin reduces food intake and
weight gain in rats via activation of GPR3, an orphan
G-protein coupled receptor [54]. Therefore, one gene
produces two products with opposing metabolic effects,
which are exercised through different receptors.
Serum ghrelin concentrations vary widely through-
out the day, with higher values during sleep, pre-pran-
dial elevations, and falls after meals. This pattern of se-
cretion was the origin of the concept of ghrelin as
a ”hunger hormone”, responsible for meal initiation.
However, it is more likely that the physiological role of
ghrelin is to prepare the body for an influx of metabolic
energy [55–57]. Ghrelin secretion differs between lean
and obese, which might have some relevance for the
pathogenesis of obesity. The postprandial falls of serum
ghrelin concentrations are proportional to energy intake
in lean subjects, but not in obese subjects. Moreover, obe-
sity is associated with a much lower reduction of post-
prandial ghrelin levels and an absence of nocturnal ele-
vations as seen in subjects of normal weight [5, 6, 58].
Gastric secretion of ghrelin may be influenced by
numerous factors, such as administration of glucose and
insulin, activation of somatostatin receptors, the cho-
linergic system, GLP-1 (glucagon-like peptide 1), PYY
(peptide YY), oxyntomodulin, thyroid hormones, and
testosterone. Ghrelin levels are inversely related to BMI,
with higher values observed in anorexia nervosa and
cachexia, and lower levels in obesity. An exception to
this rule is Prader-Willi Syndrome, in which obesity is
associated with increased ghrelin concentrations in se-
rum. Changes in body weight are accompanied by
changes in ghrelin levels, which increase with weight
loss and decrease with weight gain [52, 53].
Ghrelin stimulates food intake by acting in the
ARC nucleus, in a pattern representing a functional an-
tagonism to leptin. The orexigenic action of ghrelin oc-
curs independently of its effects on GH secretion. Gh-
relin reaches the hypothalamus through the circulation,
and the brain stem through vagal innervation. The in-
tegrity of the vagus nerve is crucial for ghrelin effects
since vagotomy prevents its orexigenic effect in animal
Table II. Gastrointestinal and pancreatic peptides involved in the appetite regulation
Tabela II. Peptydy żołądkowo-jelitowe i trzustkowe wpływające na regulację apetytu
Peptide Site of production Site of Action Effects on food intake
Receptor Hypothalamus Brainstem Vagal nerve
Ghrelin Gastric X/A-like cells GHS-R X X X Increase
CCK Intestinal I cells: CCK1R X X X Decrease
Duodenum Jejunum
GLP-1 Intestinal L cells: GLP1R X? X? X Decrease
Ileum
Colon
OXM Intestinal L cells: GLP1R X? Decrease
Ileum Others ?
Colon
PYY3–36 Intestinal L cells: Y2R X X X Decrease*
Ileum
Colon
PP Pancreatic F Cells Y4R, Y5R X X Decrease*
*central administration yields opposite results; GHS — growth hormone secretagogues; CCK — cholecystokinin; GLP-1 — glucagon-like peptide-1;
OXM — oxyntomodulin; PYY — peptide YY; PP — pancreatic polypeptide; X? — unknown effect
201
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 2 (61)
PR
A
C
E 
PO
G
LĄ
D
O
W
E
models and humans [52, 53]. In addition, ghrelin can
be produced in the brain by a group of neurons adja-
cent to the third ventricle. These neurons form connec-
tions with other orexigenic and anorexigenic pathways,
giving rise to a central circuit with potential involve-
ment in energy homeostasis.
Ghrelin and GHS-R knock-out animals have no sig-
nificant changes in food intake and body weight [59,
60]. However, the lack of ghrelin and GHS-R make the
animals resistant to diet-induced obesity and favours
the use of fat as an energy substrate when these animals
are subjected to a fat-rich diet [60, 61]. In addition, the
absence of ghrelin in ob/ob mice attenuates the diabetic
phenotype but not obesity in these animals, supporting
the role of ghrelin in the glucose metabolism [62]. Taken
together, these data show a potential for future use of
ghrelin antagonists and agonists in the treatment of an-
orexia nervosa and cachexia as well as in the prevention
of weight recovery in obesity [5, 8, 51].
Pancreatic polypeptide, enterostatin, and amylin
Pancreatic polypeptide (PP) is a 36-amino acid pep-
tide produced in the endocrine pancreas and released
into the circulation after meals in proportion to their
caloric content. PP blood levels are lower in the early
hours of the morning and highest at night, with post-
prandial elevations that last up to six hours after the
meal. Peripheral administration of PP promotes reduced
food intake in rodents and humans, but this is not ob-
served with central injection. Obese animals are less
sensitive to the effects of PP than those of normal
weight. The mechanism of PP action is not fully estab-
lished, but possibly involves activation of Y4 and Y5
receptors in the area postrema of the ARC nucleus. PP
sends anorexigenic signals via the brainstem and hy-
pothalamic neuropeptides, and modulates the expres-
sion of other peripheral peptides such as ghrelin. This
latter mechanism may explain the efficacy of PP infu-
sion in promoting a 12% reduction of food intake in
patients with Prader-Willi Syndrome. Another poten-
tial mechanism of action could be a delay in gastric
emptying, but this seems to occur only in animal mod-
els and not in humans [3, 5].
The exocrine pancreas is also responsible for the pro-
duction of enterostatin, a peptide secreted in response
to fat intake to facilitate its digestion. Although the ad-
ministration of enterostatin in animals reduces fat intake,
no significant effects have been observed in humans [6].
Amylin, a peptide co-secreted with insulin, inhibits gas-
tric emptying, gastric acid secretion, and glucagon secre-
tion, and reduces food intake and meal sizes in animals.
The synthetic analogue of amylin, pramlintide, has been
shown to cause a modest and gradual reduction in weight
over 26 weeks in diabetic patients [6].
Peptide YY
Peptide YY is structurally related to PP and NPY. This
peptide is produced throughout the gut, with tissue
concentrations that increase distally, reaching higher
levels in the colon and rectum. The predominant form
of PYY stored in intestinal cells (together with GLP-1)
and released into the circulation is PYY3–36, with the N-
terminal truncated by the enzymatic action of dipepti-
dyl peptidase (DPP-IV). Peptide YY3–36 is secreted in pro-
portion to the amount of calories in the meal, with se-
rum concentrations increasing rapidly in the first two
hours and remaining high for up to six hours after the
meal. The secretion is mediated by neural reflex and by
direct contact of nutrients. Fat intake promotes higher se-
cretion of PYY3–36 than carbohydrates and proteins [3, 5].
The peripheral administration of physiological dos-
es of PYY3–36 leads to significant reduction of food in-
take in rodents. However, the use, adaptation, and cre-
ation of an appropriate environment are essential to
observe the effects of PYY3–36 on appetite [5, 8]. In con-
trast, the central administration of PYY3–36 increases the
appetite in animals. In normal weight volunteers, in-
travenous PYY3–36 reduces energy intake by 30%. In obe-
sity, circulating levels of PYY3–36 are relatively low and
its postprandial secretion is deficient in comparison with
lean individuals. However, administration of PYY3–36 in
obese individuals may also result in reduced appetite
and caloric intake. Nonetheless, it is possible that the
reduction in food intake promoted by PYY3–36 in humans
might be secondary to side effects such as nausea and
aversion to food [3, 5, 8, 51].
The most likely mechanism of action of PYY3–36 is
through its binding to the Y2-pre-synaptic inhibitory
receptors expressed in the NPY/AgRP neurons. This
action inhibits the NPY production and results in in-
creased activity of POMC/CART neurons. However, the
PYY3–36 acts even in the absence of the melanocortin
system, as observed in genetically modified animals that
do not express POMC or MC4R [63]. Additionally, ad-
ministration of PYY3–36 reduces ghrelin levels, and this
may be an additional factor that contributes to its anor-
exigenic effect [3].
Glucagon-like peptide 1 (GLP-1)
The pro-glucagon gene is cleaved in different products
by the enzymes convertase 1 and convertase 2, and this
process varies among the tissues. In the pancreas, the
main product of this cleavage is glucagon, whereas in
the intestine the main products are GLP-1 and GLP-2.
GLP-1 is released into the circulation after meals, phys-
iologically acting as an incretin that promotes increased
pancreatic insulin secretion and, consequently, influ-
ences glucose homeostasis. Some studies show that cir-
culating levels of GLP-1 are lower in obese patients and
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increase with weight loss. The half-life of GLP-1 is very
short, being rapidly degraded by the DPP-IV [3, 5].
Central and peripheral actions of GLP-1 are impor-
tant in the regulation of energy balance. GLP-1 recep-
tors are present in hypothalamic nuclei and brain stem
areas known to be involved with energy balance. When
centrally injected in rodents, GLP-1 produces anorexia,
induces satiety, and increases energy expenditure, lead-
ing to reduced body weight if given over a long period.
In lean and obese subjects, peripheral infusion of GLP-
1 causes a dose-dependent reduction of caloric intake.
Similarly, the use of exenatide and DPP-IV inhibitors
— drugs currently available for the treatment of type 2
diabetes — is associated with modest but progressive
weight loss and reductions in both fasting and postpran-
dial glycaemia in diabetic patients [64]. However, the
use of these agents as anti-obesity drugs in non-diabet-
ic individuals is limited due to hypoglycaemic events.
Oxyntomodulin
Oxyntomodulin (OXM) is another product of the pro-
glucagon gene, which is released from intestinal cells
into the circulation in proportion to caloric intake. OXM
inhibits gastric acid secretion, reduces food intake when
administered centrally to rodents or peripherally in ro-
dents and humans, and reduces body weight and fat
mass when injected chronically. The weight loss ob-
served is greater than it would be expected by a reduc-
tion in food intake, indicating that OXM promotes in-
creased energy expenditure. In humans, OXM admin-
istration also reduces the levels of circulating ghrelin,
which may contribute to its effects on appetite [3, 5].
The most likely mechanism of action of OXM on
energy homeostasis is through its binding to the GLP-1
receptor. Although OXM binds the GLP-1 receptor with
lower affinity than GLP-1, they are equally effective in
causing anorexia. Thus, differences in the biological ef-
fects of OXM and GLP-1 may be due to variations in
tissue penetration, degradation, or intracellular signal-
ling pathways [5]. However, the existence of a specific
receptor for OXM cannot be completely ruled out. Pre-
liminary results of short-term studies indicate that OXM
could be the first treatment for obesity that combines
appetite suppression without tachyphylaxis with in-
creased energy expenditure [51, 65].
The endocannabinoid system
The anti-emetic and appetite-stimulating properties of
Cannabis sativa have been known for centuries, but the
isolation and characterization of its active compound
D9-tetrahydrocannabinol (THC) was only performed in
the sixties. THC and its synthetic analogue nabilone
have been prescribed to treat nausea and vomiting as-
sociated with chemotherapy and weight loss associat-
ed with acquired immunodeficiency syndrome [66]. In
the last two decades, new insights into the mechanisms
of action of THC have been acquired with the cloning
of two cannabinoid receptors (CB1 and CB2) and the
discovery of their main endogenous ligands (endocan-
nabinoids): N-arachidonoyl-ethanolamine (ananda-
mide) and 2-arachidonoyl glycerol (2-AG). Endocannab-
inoids are synthesized from arachidonic acid and are
rapidly hydrolyzed to inactive compounds by the ac-
tion of specific catalytic enzymes. Endocannabinoids,
CB1 and CB2 receptors, and enzymes responsible for
biosynthesis and degradation constitute the endocan-
nabinoid system, which is present in the brain and in
various peripheral tissues [7, 66, 67].
Endocannabinoids modulate neuronal activity
through the process of retrograde suppression of neu-
rotransmitter release. In this process, the actions of neu-
rotransmitters in postsynaptic neurons stimulate rap-
id, transitory, and on-demand production of endocan-
nabinoids from phospholipid precursors located on the
cell membrane. Anandamide and 2-AG are released and
pass through the synapse in a retrograde pathway, in-
teracting with CB1 receptors on presynaptic axons,
which result in a variety of intracellular events that
modulate the activity of these neurons. The final result
of the endocannabinoid action depends on the excitato-
ry or inhibitory nature of the synapse, resulting in re-
pression or release of neuronal transmission [7, 66, 67].
While CB1 is mainly involved with anabolic func-
tions of the endocannabinoids, CB2 is more related with
the immune system. CB1 is widely and abundantly dis-
tributed in tissues involved with energy homeostasis,
including brain areas such as the hypothalamus, brain-
stem, and mesolimbic region, and peripheral tissues
such as the GIT, fat, liver, muscle, thyroid, and pancre-
as. The binding of endocannabinoids to CB1 receptors
results in increased appetite, weight gain, lipogenesis,
and lower insulin sensitivity. In the hypothalamus, en-
docannabinoids increase the production of orexigenic
neurotransmitters and reduce the anorexigenic signals
[68]. In the reward centre of the mesolimbic region, they
promote motivation to seek and consume palatable
food, while in the brainstem they block the signals of
nausea and satiety transmitted by the vagus nerve. Pe-
ripherally, endocannabinoids facilitate the absorption
of nutrients in the GIT, stimulate lipogenesis and im-
pair glucose uptake in muscles [7]. Accordingly, CB1
knock-out mice are hypophagic, lean, insulin sensitive,
and resistant to diet-induced obesity [69].
The adipose tissue and the GIT are closely integrat-
ed, and the peripheral signals are able to determine
changes within the activity of the central endocannab-
inoid receptor. Central effects of leptin result in reduced
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levels of endocannabinoids due to interference with
2-AG synthesis and increased anandamide degradation
[67, 68]. In contrast, increased circulating levels of ghre-
lin in situations of food deprivation are associated with
higher endocannabinoid activity, suggesting that the
orexigenic effect of ghrelin occurs, at least in part, by
activation of the endocannabinoid system [7, 67, 68].
It has been hypothesized that human obesity could
be caused by an overactive endocannabinoid system
[69]. Transient activation of this system, as seen after
fasting and/or exposure to palatable foods, induces in-
creased appetite, smaller satiety, increased lipogenesis,
and reduced energy expenditure. Thus, sustained hy-
peractivity could lead to hyperphagia with progressive
and excessive accumulation of fat and subsequent de-
velopment of obesity and metabolic syndrome (Fig. 2).
Excessive endocannabinoid activity, in turn, could be
caused by a high-fat diet that would provide more sub-
strate for the synthesis of anandamide and 2-AG, and
would be perpetuated with the development of leptin
resistance that often occurs in obesity.
In recent years, the development of CB1 antagonists
has appeared to be a promising therapy for obesity and
metabolic syndrome [7, 8]. CB1 antagonists are able to
reduce appetite and body weight in genetically obese
animals such as ob/ob, db/db mice and Zucker rats, as well
as in animal models of diet-induced obesity. In addi-
tion to weight loss, other benefits have been experimen-
tally observed including improvements in insulin sen-
sitivity, lipid profile and hepatic steatosis, and increased
adiponectin levels. In humans, clinical protocols with
the CB1 antagonist rimonabant (Rimonabant In Obesi-
ty — RIO Studies), lasting up to two years and includ-
ing more than 6600 overweight and obese participants
with or without diabetes and dyslipidemia, were car-
ried out some years ago [70]. In brief, these studies
showed that 20 mg of rimonabant significantly reduced
body weight (a mean loss of 7.4 kg after 2 years), with
one third of participants showing a reduction of 10% or
more in body weight. Metabolic improvements were
reported, including elevation of HDL-cholesterol, re-
duced triglycerides, increased adiponectin, decreased
C-reactive protein, improvement in HOMA-IR index,
and reduction in glycosylated haemoglobin in diabetic
patients. However, depression and anxiety, varying
from mild to severe, developed in a substantial number
of patients leading to discontinuation of the drug [71].
Conclusions
Several signals produced by the adipose tissue, GIT, and
pancreas are involved with energy homeostasis and
body weight regulation. The hypothalamus, particularly
the ARC, is responsible for integrating these peripheral
signals with other information that arises from the en-
docannabinoid system and also from the internal and
external milieu (Fig. 3). The analysis of all these input
signals triggers several compensatory responses to
maintain a balance between energy intake and expen-
diture. The malfunctioning of one or more component
Figure 2. Overactive endocannabinoid system as a potential cause
of human obesity. Transient activation of the endocannabinoid
system induces increased appetite, smaller satiety, increased
lipogenesis, and reduced energy expenditure. The ingestion of
highly palatable foods, especially those associated with high-fat diet,
would provide greater quantities of substrates for the synthesis of
anandamide (ADA) and 2 arachidonoyl glycerol (2-AG), causing
hyperactivity of the endocannabinoid system and consequent
hyperphagia, fat accumulation, obesity, and metabolic syndrome.
The development of obesity-associated leptin-resistance would
perpetuate the endocannabinoid hyperactivity
Rycina 2. Nadaktywny układ endokanabinoidowy jako potencjalna
przyczyna otyłości u ludzi. Przejściowa aktywacja układu
endokanabinoidowego powoduje wzrost apetytu, zmniejsza  sytość,
wzmaga lipogenezę i zmniejsza wydatek energetyczny. Spożywanie
smacznego jedzenia, szczególnie sprzyjającemu diecie wysoko-
tłuszczowej, dostarczyłoby więcej produktów do syntezy anandaminy
(ADA) i 2 arachidonolu glicerolu (2-AG), powodując nadaktywność
układu endokanabinoidowego, a następnie hyperfagię, gromadzenie
tłuszczu, otyłość i zespół metaboliczny. Rozwój oporności na
leptynę związanej z otyłością będzie powodowało wzrost nadaktywność
układu endokanabinoidowego
204
Neuroendocrine body weight regulation César Luiz Boguszewski et al.
PR
A
C
E 
PO
G
LĄ
D
O
W
E
Figure 3. Energy balance regulation through interactions between the central nervous system (CNS), gastrointestinal tract (GIT),
pancreas and adipose tissue (AT). The elements inside the large box represent the hypothalamic nuclei (PVN, paraventricular nucleus;
HL, lateral hypothalamus, ARC, arcuate nucleus) with orexigenic neurons (NPY/AgRP, MCH and ORX), anorexigenic neurons (POMC/
/CART and CRH/TRH) and their connections. The open circles indicate the locations of the CB1 receptors of the endocannabinoid
system. Stimulatory or inhibitory effect of a peptide on the neuronal population is indicated by the positive or negative signs, respectively.
The actions carried out through the vagus nerve (VN) are indicated by dotted arrows. Receptors are represented in hypothalamic neurons
and VN: Ob-Rb (leptin) in NPY/AgRP and POMC/CART neurons and in the stomach; IR (insulin) in NPY/AgRP and POMC/CART
neurons; GHS-R (ghrelin) in NPY/AgRP neurons and in the stomach; Y2R [peptide YY (PYY3-36)] in NPY/AgRP neurons; MC4R
(melanocortin) in CRH/TRH neurons; CCKR1 [cholecystokinin (CCK)] in the stomach and in the brain stem (BS); GLP-1R [glucagon-
like peptide (GLP-1) and oxyntomodulin (OXM)] in the stomach and in the BS. CCKR1 and GLP-1R receptors in the BS indicate
a direct action on this area. Leptin and insulin are „adiposity signals” that help in regulating longterm body stores energy, while the GIT
peptides (ghrelin, PPY, OXM, CCK and GLP-1) act mainly as „satiety signals”, determining the start and end of the meal and the
interval between meals.
NPY — neuropeptide Y; AgRP — agouti-related peptide; POMC — pro-opiomelanocortin; CART — cocaine- and amphetamine-
regulated transcript; a-MSH — melanocyte-stimulating hormone (melanocortin); CRH — corticotropinreleasing hormone; TRH —
thyrotropin-releasing hormone; MCH, melanin-concentrating hormone; ORX — orexins
Rycina 3. Regulacja równowagi energetycznej przez interakcje między ośrodkowym układem nerwowym (OUN), układem pokarmowym
(GIT), trzustką i tkanką tłuszczową (AT). Elementy w dużym kwadracie odpowiadają jądrom podwzgórza (PVN, jądro przykomorowe;
HL, podwzgórze boczne; ARC, jądro łukowate) z neuronami oreksygenicznymi, anoreksygenicznymi, i ich połączeniami. Kółka wskazują
na lokalizację receptorów CBI układu endokannabinoidowego. Efekt stymulujący lub hamujący białek na populację neuronów jest wskazany
przez znaki dodatnie lub ujemne, odpowiednio. Aktywności przewodzone przez nerw błędny (VN) wskazują kropkowane strzałki. Receptory
w neuronach podwzgórza i nerwu błędnego: Ob-Rb (leptyna) w neuronach NPY/AgRP i POMC/CART i w żołądku; IR (insulina)
w neuronach NPY/AgRP i POMC/CART, GHS-R (grelina) w neuronach NPY/AgRP i w żołądku, Y2R[peptyd YY (PYY3-36)] neuronach
NPY/AgRP; MC4R (melanokortyna) w neuronach CRT/TRH; CCKR1 [cholecystokinina] w żołądku i pniu mózgu , GLP-1R [(peptyd
podobny do glukagonu (GLP-1) i oksyntomodulina (OXM)] w żołądku i pniu mózgu. CCKR1 i GLP-1R receptory w pniu mózgu (BS)
wskazują na bezpośrednią aktywność tego obszaru. Leptyna i insulina są „sygnałami tłuszczowymi” które pomagają w regulacji tworzenia
długoterminowych zapasów energetycznych, podczas gdy peptydy GIT(grelina, PPY, OXM, CCK i GLP-1) działają głównie jako „sygnały
sytości” określając początek i koniec posiłku oraz przerwy między posiłkami.
NPY — neuropeptyd Y, AgRP — białko aguti; POMC — proopiomelanokortyna; CART — transkrypt regulowany przez kokainę
i amfetaminę; a-MSH — hormon stymulujący melanocyty (melanokortyna), CRH — hormon uwalniający kortykotropinę; TRH – hormon
uwalniający tyreotropinę; MCH — hormon zwiększający stężenie melaniny; ORX — oreksyny
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of this complex machinery might result in an energy
imbalance and significant changes in body weight. The
outstanding scientific advances regarding the knowl-
edge of this machinery, particularly in the last two de-
cades, encourage the future development of safer and
more effective therapeutic approaches against obesity
and other nutritional and metabolic disorders.
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